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Abstract
Objective To examine the risk of colorectal cancer after orlistat initiation
in the UK population.
Design Retrospective matched cohort study.
Setting Data from the UK Clinical Practice Research Datalink from
September 1998 to December 2008.
Participants 33 625 adults aged 18 years or over who started treatment
with orlistat; each orlistat initiator was matched to up to five non-initiators
(n=160 347) on age, sex, body mass index, and calendar time.
Main outcome measures Associations between orlistat initiation and
the risk of colorectal cancer, assessed by calculating hazard ratios with
propensity score adjusted Cox proportional hazard models.
ResultsOf 193 972 patients with a median age of 47 (interquartile range
37-57) years, 77% were women and approximately 90% were obese
(body mass index ≥30). Orlistat initiators were more likely to have a
previous history of diabetes or hypertension and to receive prescriptions
for anti-diabetes drugs, statins, and aspirin compared with non-initiators.
In the intention to treat analysis, 57 colorectal cancer events were
identified among orlistat initiators and 246 among non-initiators, with
median follow-up times of 2.96 and 2.86 years, respectively. The
calculated incidence rate of colorectal cancer per 100 000 person years
was 53 (95% confidence interval 41 to 69) for orlistat initiators and 50
(44 to 57) for non-initiators. Orlistat initiation was not associated with a
higher risk of colorectal cancer (adjusted hazard ratio 1.11, 95%
confidence interval 0.84 to 1.47). Findings were robust in the as treated
analyses and in patients who were aged 50 years or over, were morbidly
obese, or had a history of diabetes.
Conclusions This study found no evidence of an increased risk of
colorectal cancer after the initiation of orlistat. It is limited by the relatively
short follow-up time, and the possibility of adverse effects of long term
orlistat use on risk of colorectal cancer cannot be excluded.
Introduction
Orlistat is an anti-obesity drug that reduces the absorption of
dietary fat by inhibiting lipase and is currently approved for
both prescription (Xenical, Roche) and over the counter (Alli,
GlaxoSmithKline) sale in the United States and Europe. Long
term treatment with orlistat has been shown to significantly
reduce weight and waist circumference and to have beneficial
effects on blood pressure, lipids, and type 2 diabetes.1-5
An animal study found that orlistat was associated with a
significant increase in the number of colonic aberrant crypt foci,
independent of high fat diet.6 This result is supported by another
preclinical study, which showed that orlistat induced colonic
cell proliferation and severe crypt alternation.7 Aberrant crypt
foci are putative precursors of colon cancer, although
controversy has arisen about aberrant crypt foci as a biomarker
of colorectal cancer.8-10 An analysis of pooled clinical trials
conducted by orlistat manufactures found no statistically
significant difference in risk of colorectal cancer between orlistat
and placebo groups.11Nevertheless, the pooled analysis showed
a numerical imbalance in colorectal carcinoma favoring placebo
and was not adequately powered to detect a clinically relevant
increased risk. Six of 9717 patients taking orlistat developed
colon cancer compared with only one of 7912 patients on
placebo. Furthermore, randomized trials tend to recruit younger
and healthier patients. On the basis of a review of available data
and literature, the US Food and Drug Administration concluded
that no evidence existed of a causal relation between use of
orlistat and the risk of colorectal cancer.12
Orlistat is currently the top selling drug in the global market of
anti-obesity drugs, with worldwide sales of $663m (£427m;
€496m) in 2011, according to a report from EvaluatePharma.13
Given such extensive use of orlistat, the lack of data from
population based studies on its effects on the risk of colorectal
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cancer is a major concern. In this study, we sought to investigate
whether orlistat initiation would affect the risk of colorectal
cancer in a large cohort of adults in the United Kingdom.
Methods
We did a retrospective matched cohort study using data from
the UK Clinical Practice Research Datalink (CPRD) from
September 1998 to December 2008. Orlistat was available only
by prescription in the UK during our study period.
We considered patients to be new users of orlistat if they were
aged 18 years or over, had been actively recorded in the CPRD
for at least 12 months before starting orlistat treatment without
use of any prescription for anti-obesity drugs (orlistat,
sibutramine, rimonabant, phentermine, and diethylpropion), and
had a bodymass index recordedwithin 12months before starting
treatment. We further restricted new users of orlistat to those
who had a second orlistat prescription on or before the end of
drug supply of the first orlistat prescription plus a 15 day grace
period. We used the date of the second prescription to define
cohort entry (the start date). For each orlistat initiator, we
randomly selected up to five non-initiators from patients who
had bodymass index recorded and did not start any prescription
anti-obesity drug on the start date of the corresponding orlistat
initiator or in the previous 12 months, further matched on age,
sex, and body mass index (within 1 unit). We assigned each
non-initiator the same start date of his/her matched orlistat
initiator. We excluded patients in both cohorts if they had
diagnosis of colorectal adenoma, familial polyposis, or any type
of cancer (except non-melanoma skin cancer) before the start
date.
Incident colorectal cancer was the outcome in this study. We
ascertained diagnosis of colorectal cancer through Read codes
during follow-up, including malignant neoplasm and carcinoma
in the colon and rectum.
We did both intention to treat and as treated analyses. In the
intention to treat analysis (first treatment carried forward), we
considered patients to be exposed to the initial treatment (orlistat
versus none) until administrative censoring, ignoring any
subsequent changes in treatment. In the as treated analysis, we
considered orlistat initiators to be exposed until 180 days after
the discontinuation of orlistat or an additional prescription for
any other anti-obesity drug; we censored non-initiators for
initiation of any anti-obesity drug. We chose 180 days to allow
for a carry-over effect or latency period of cancer detection. In
both analyses, the follow-up started at 180 days after the start
date to account for an induction period of cancer pathogenesis
in both cohorts and ended with the earliest of death, any type
of cancer (except non-melanoma skin cancer), migration out of
the healthcare system, or end of the study period.
Statistical analysis
We used a Cox proportional hazards model with robust variance
to estimate the hazard ratios of colorectal cancer, overall and
over time, and their corresponding 95% confidence intervals.
To control confounding, we first assembled cohorts bymatching
and then controlled for remaining imbalances by using
propensity scores weighting.14 15We used this two step approach
because we intended to control tightly for age, sex, and body
mass index, which are the most important confounders in this
study, without the need to rely on correct specification of
multivariable models.
We did sensitivity analyses to assess the robustness of our
assumptions of induction and latency periods. We repeated the
main analysis with various lengths of time for induction and
latency periods. Note that intention to treat analysis is an
extreme form of (infinite) latency. We also did subgroup
analyses. We used SAS software (version 9.2) for all statistical
analyses.
Results
This study included 33 625 orlistat initiators and 160 347
matched non-initiators. Of all non-initiators, 20 664 started
anti-obesity drugs during follow-up. Table 1⇓ compares the
characteristics of orlistat initiators and non-initiators. Compared
with non-initiators, orlistat initiators had a slightly higher
prevalence of diabetes and hypertension at baseline and were
more likely to receive drugs, including oral anti-diabetes drugs,
statins, and non-steroidal anti-inflammatory drugs. After
propensity scores weighting, baseline characteristics were well
balanced between orlistat initiators and non-initiators.
Table 2⇓ shows incidence rates and hazard ratios of colorectal
cancer. In the intention to treat analysis, we observed 57
colorectal cancers among orlistat initiators and 246 among
non-initiators during 106 708 and 488 526 person years of
follow-up. The incidence rate of colorectal cancer per 100 000
person years was 53 (95% confidence interval 41 to 69) for
orlistat initiators and 50 (44 to 57) for non-initiators. The hazard
ratio of colorectal cancer comparing orlistat initiators with
non-initiators was 1.11 (95% confidence interval 0.84 to 1.47)
after propensity scores weighting. In the as treated analysis, the
mean follow-up time and the number of colorectal cancer cases
were lower owing to treatment changes, whereas the hazard
ratio estimates were similar to the results of the intention to treat
analysis. We further examined the effect of orlistat on the risk
of colorectal cancer over the follow-up time (fig 1⇓), and we
observed no increased risk of colorectal cancer and no clear
trend of the hazard ratios over time.
We did sensitivity analyses to evaluate the robustness of the
results with respect to the assumptions of induction and latency
periods (tables 3⇓ and 4⇓). The absence of an effect of orlistat
initiation on the risk for colorectal cancer was consistent through
the range of induction and latency periods assessed in both
intention to treat and as treated analyses. We also did subgroup
analyses. The results showed that orlistat was not associated
with an increased risk of colorectal cancer in analyses stratified
according to age (≥50 or <50 years), sex, body mass index (≥35
or <35), or the presence or absence of diabetes at baseline in
both intention to treat and as treated analyses (fig 2⇓).
Discussion
In our large, non-experimental cohort study, starting orlistat
treatment was not associated with an increased risk of colorectal
cancer among patients aged 18 years or over in the UK Clinical
Practice Research Datalink (CPRD). These findings were
consistent in sensitivity analyses and subgroup analyses. Orlistat
initiators and matched non-initiators had similar baseline
characteristics, with only slight difference in previous diagnosis
of and treatment for diabetes and hypertension. Our findings
provide evidence that use of orlistat does not alter the risk of
colorectal cancer.
Although our estimates were based on a small number of events
despite the size of the study population, the adjusted hazard
ratio was 1.11 with a 95% confidence interval ranging from
0.84 to 1.47, showing not only acceptable precision of our
estimate but also that our data are not compatible with a
meaningful harmful effect of orlistat treatment on the risk of
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colorectal cancer. Our findings support the US Food and Drug
Administration’s conclusion of no increased risk of colorectal
cancer associated with the use of orlistat. The FDA’s report was
based on the negative results from pooled clinical trials and a
small number of cases of colon cancer from the spontaneous
adverse event reporting system. Our study, based on a large,
population based healthcare database, represents people actually
taking orlistat in the real world, who tend to be different from
the participants in clinical trials.
Recent studies showed that a reduction in body mass index
could decrease the risk of colon cancer,16-18 so our results need
to be considered in light of the potential protective effect of
orlistat induced weight loss in obese people. Unfortunately, we
do not have enough follow-up data on body mass index to
estimate the magnitude of the effect of orlistat induced weight
loss. Given the average orlistat induced weight loss and a short
follow-up time in our study, we would not expect a relevant
protective effect of orlistat induced weight loss on the incidence
of colorectal cancer. Moreover, although this is of scientific
interest, we would mainly be interested in the overall effect of
orlistat on colorectal cancer incidence from an individual or
public health perspective.
In the sensitivity analyses for induction and latency periods, the
results were not substantially altered by the length of induction
and latency periods, and the absence of association between
orlistat and colorectal cancer was consistent throughout all
scenarios. Risk of colorectal cancer may change over time after
orlistat initiation. We did not observe a monotonic trend of
hazard ratios of colorectal cancer over time (fig 1⇓). Although
higher risks of colorectal cancer were seen with follow-up of
24 months or longer, the estimates were hampered by wide
confidence intervals owing to a small number of colorectal
cancer events.
Limitations of study
Our study had several limitations. Non-adherence is of concern.
To increase the chances that patients were truly exposed to
orlistat, we required at least two continuous prescriptions. We
were unable to use an active comparator cohort because the
number of patients starting weight reduction drugs other than
orlistat was too small. We recognize that the follow-up time is
not long enough to observe an effect on initiation of colorectal
cancer, so all we can say is that orlistat does not seem to have
an effect on promotion of colorectal cancer. Thus, our analysis
cannot exclude the possibility of an increased risk of colorectal
cancer after long term use of orlistat. Nevertheless, in our data,
the short follow-up time based on as treated analysis also
indicates that most patients do not take orlistat continuously for
a prolonged time.
As this was a non-experimental study, our results may be
affected by unmeasured confounding. Fat distribution, usually
measured as waist circumference, is a moderate risk factor for
colorectal cancer, partially independent of body mass index,
and might be positively correlated with the probability of taking
orlistat.19 20Unfortunately, the CPRD fails to capture information
on fat distribution. Common side effects of orlistat are
gastrointestinal, such as abdominal pain or oily stool, potentially
leading to diagnostic endoscopies. This could lead to an earlier
diagnosis of (asymptomatic) colorectal cancer, resulting in an
increased hazard ratio, but cannot explain our finding; on the
other hand, endoscopies also could lead to early removal of
colonic adenomatous polyps, resulting in a reduced long term
risk of colorectal cancer, but we would expect such a beneficial
effect to take several years to become apparent. We also
examined the frequency of patients who underwent screening
for colorectal cancer within one year after cohort entry and
found no difference between orlistat initiator and non-initiators
cohorts (0.37% v 0.38%). The generalizability of the results is
also limited by the lack of information on race/ethnicity in the
CPRD.
Conclusions
Our study provides no evidence of an increased risk of colorectal
cancer after starting orlistat treatment in UK adults. The study
is limited by the relatively short follow-up time, and we cannot
exclude the possibility of adverse effects of long term orlistat
use on risk of colorectal cancer.
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Tables
Table 1| Matched cohort characteristics at baseline, before and after propensity score weighting
Weighted non-initiators* (%)
No (%)
Variable Matched non-initiators (n=160 347)Orlistat initiators (n=33 625)
77.52124 647 (77.74)26 030 (77.41)Female sex
47 (36-57)47 (37-57)47 (37-57)Median (IQR) age, years
36.3 (32.7-40.4)35.6 (32.1-39.6)36 (32.4-40.4)Median (IQR) BMI
BMI category:
0.451006 (0.63)174 (0.52)<25
8.6416 909 (10.55)3173 (9.44)25-30
32.0956 460 (35.21)11 253 (33.47)30-35
58.8385 972 (53.62)19 025 (56.58)≥35
Smoking status:
50.1988 103 (54.95)16 932 (50.36)Never
20.6734 457 (21.49)6941 (20.64)Current
25.5633 402 (20.83)8546 (25.42)Past
3.594385 (2.73)1206 (3.59)Unknown
Alcohol use:
10.4313 259 (8.27)3488 (10.37)Never
67.42113 466 (70.76)22 719 (67.57)Current
19.6030 563 (19.06)6575 (19.55)Past
2.543059 (1.91)843 (2.51)Unknown
0.65908 (0.57)213 (0.63)Family history of bowel cancer
0.40559 (0.35)145 (0.43)Colorectal cancer screening
0.15141 (0.09)52 (0.15)Type 1 diabetes




0.37438 (0.27)110 (0.33)Heart failure
0.26273 (0.17)96 (0.29)Myocardial infarction
0.14183 (0.11)33 (0.10)Gastrointestinal ulcer
0.21206 (0.13)69 (0.21)Gastrointestinal bleeding
0.30447 (0.28)97 (0.29)Rheumatoid arthritis
4.633597 (2.24)1508 (4.48)Insulin treatment
13.4611 965 (7.46)4434 (13.19)Oral anti-diabetes drug
7.558233 (5.13)2495 (7.42)Hormone therapy
19.3920 369 (12.70)6415 (19.08)Statin
13.9014 596 (9.10)4603 (13.69)Aspirin
32.0534 651 (21.61)10 662 (31.71)Non-selective NSAID
4.413726 (2.32)1429 (4.25)COX 2 inhibitor
0.24314 (0.20)84 (0.25)Vitamin D
BMI=body mass index; COX 2 inhibitor=cyclo-oxygenase-2 selective inhibitor; IQR=interquartile range; NSAID=non-steroidal anti-inflammatory drug.
*Propensity score model included age (continuous), sex, BMI (continuous), lifestyle factors (smoking (yes, no, unknown), alcohol use (yes, no, unknown)),
comorbidity (diabetes, hypertension, hyperlipidemia, arrhythmias, heart failure, myocardial infarction, gastrointestinal ulcer, gastrointestinal bleeding, and rheumatoid
arthritis), drug use (insulin, oral anti-diabetes drugs, aspirin, NSAIDs, COX 2 inhibitors, statins, and hormone therapies), family history of bowel cancer, and previous
screening for colorectal cancer; all variables were defined during 12 month period before cohort entry date and were controlled for by standardizing to their
distribution in orlistat initiators by using weights of 1 for orlistat initiators and the odds of the estimated propensity score for non-initiators.15
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Intention to treat (ITT) analysis‡§
1.11 (0.84 to 1.47)1.06 (0.80 to 1.40)53 (41 to 69)2.96 (1.43-5.37)106 70831 05557Orlistat initiators
1.001.0050 (44 to 57)2.86 (1.34-5.24)488 526146 133246Non-initiators
As treated (AT) analysis‡
0.99 (0.56 to 1.77)0.95 (0.54 to 1.66)47 (28 to 79)0.75 (0.57-1.16)29 97131 05514Orlistat initiators
1.001.0053 (47 to 60)2.40 (1.08-4.60)434 648146 133230Non-initiators
*Because non-initiators were matched on age, sex, and body mass index, unweighted hazard ratios were controlled for these matching variables and standardized
to distribution of these variables in orlistat initiators.
†Propensity score weighted hazard ratios were additionally controlled for smoking, alcohol use, diabetes mellitus, hypertension, hyperlipidemia, arrhythmias, heart
failure, myocardial infarction, gastrointestinal ulcer, gastrointestinal bleeding, rheumatoid arthritis, insulin, oral anti-diabetes drugs, aspirin, non-steroidal
anti-inflammatory drugs, cyclo-oxygenase-2 selective inhibitors, statins, hormone therapies, family history of bowel cancer, and previous screening for colorectal
cancer, standardized to distribution of these variables in orlistat initiators.
‡Although AT is generally preferred in studies of adverse effects because ITT would tend to mask effects owing to increasing non-adherence to treatment over
time, AT could be biased if changes in treatment during follow-up are associated with outcome; ITT ignores subsequent treatment changes and thus avoids potential
for selection bias by condition on continuous treatment during follow-up; because of this trade-off in potential biases, both ITT and AT analyses based on different
assumptions are presented; use of a time varying exposure classification would be an alternative approach, but it is not compatible with the new user design and
thus prone to time varying confounding of treatment changes during follow-up.
§On basis of ITT, 5431 cancer events were observed in whole study cohort (orlistat initiators and non-initiators combined) for overall cancer incidence rate of 791
(95% CI 770 to 812) per 100 000 person years; over study period, 4376 patients died during 657 894 person years of follow-up, resulting in all cause mortality rate
of 625 (607 to 644) per 100 000 person years; both rates were higher than in general UK population, likely explained by higher body mass index in study cohort.
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Table 3| Sensitivity analysis for induction period in intention to treat analysis
Weighted hazard ratio (95%
CI)*
Follow-up (years)—median
(interquartile range)No of observationsNo of colorectal cancersInduction period and cohort
0 days:
1.00 (0.76 to 1.32)3.20 (1.57-5.64)33 62558Orlistat initiators
1.003.03 (1.46-5.47)160 347272Non-initiators
90 days:
1.05 (0.79 to 1.39)3.07 (1.48-5.50)32 50157Orlistat initiators
1.002.93 (1.38-5.34)153 659260Non-initiators
180 days:
1.11 (0.84 to 1.47)2.96 (1.43-5.37)31 05557Orlistat initiators
1.002.86 (1.34-5.24)146 133246Non-initiators
365 days:
1.14 (0.85 to 1.53)2.72 (1.31-5.14)28 46351Orlistat initiators
1.002.63 (1.26-5.04)132 631215Non-initiators
*Propensity score weighted hazard ratios were controlled for age, sex, body mass index, smoking, alcohol use, diabetes mellitus, hypertension, hyperlipidemia,
arrhythmias, heart failure, myocardial infarction, gastrointestinal ulcer, gastrointestinal bleeding, rheumatoid arthritis, insulin, oral anti-diabetes drugs, aspirin,
non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2 selective inhibitors, statins, hormone therapies, family history of bowel cancer, and previous screening
for colorectal cancer, standardized to distribution of these covariates in orlistat initiators.
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0.77 (0.44 to 1.34)1.21 (1.06-1.60)33 62515Orlistat initiators1800
1.002.61 (1.25-4.75)160 347256Non-initiators
0.85 (0.47 to 1.52)0.97 (0.82-1.37)32 50114Orlistat initiators18090
1.002.49 (1.16-4.64)153 659244Non-initiators
0.99 (0.56 to 1.77)0.75 (0.57-1.16)31 05514Orlistat initiators180180
1.002.40 (1.08-4.60)146 133230Non-initiators
1.12 (0.56 to 2.24)0.32 (0.13-0.73)27 2349Orlistat initiators180365
1.002.32 (1.05-4.48)128 276199Non-initiators
0.89 (0.40 to 2.01)0.33 (0.14-0.76)29 7197Orlistat initiators0180
1.002.44 (1.12-4.66)141 562229Non-initiators
0.99 (0.52 to 1.90)0.55 (0.32-0.96)30 38711Orlistat initiators90180
1.002.42 (1.11-4.64)143 532230Non-initiators
0.99 (0.56 to 1.77)0.75 (0.57-1.16)31 05514Orlistat initiators180180
1.002.40 (1.08-4.60)146 133230Non-initiators
0.86 (0.52 to 1.41)1.21 (1.08-1.60)31 05518Orlistat initiators365180
1.002.47 (1.17-4.66)146 133231Non-initiators
1.03 (0.70 to 1.50)2.08 (1.43-2.45)31 05532Orlistat initiators730180
1.002.62 (1.34-4.77)146 133236Non-initiators
*Propensity score weighted hazard ratios were controlled for age, sex, body mass index, smoking, alcohol use, diabetes mellitus, hypertension, hyperlipidemia,
arrhythmias, heart failure, myocardial infarction, gastrointestinal ulcer, gastrointestinal bleeding, rheumatoid arthritis, insulin, oral anti-diabetes drugs, aspirin,
non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2 selective inhibitors, statins, hormone therapies, family history of bowel cancer, and previous screening
for colorectal cancer, standardized to distribution of these covariates in orlistat initiators.
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Figures
Fig 1 Propensity score weighted hazard ratios (95% CI) comparing orlistat initiators and non-initiators, stratified by length
of follow-up, in intention to treat (top) and as treated (bottom) analyses
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Fig 2 Propensity score weighted hazard ratios (95% CI) comparing orlistat initiators and non-initiators, stratified by age,
sex, body mass index (BMI), and history of diabetes at baseline, in intention to treat (top) and as treated (bottom) analyses
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